Cumberland Pharmaceuticals CPIX Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Acetadote | $408.79K-19.6% | $508.46K+5.5% | $482K+18.5% | $406.78K+58.5% | $256.63K+38.6% | |
| Caldolor | $4.32M-7.3% | $4.66M-9.3% | $5.14M-7.3% | $5.54M+15.5% | $4.8M-3.3% | |
| Kristalose | $8.04M-23.7% | $10.54M-10.6% | $11.8M-17.2% | $14.25M-8.7% | $15.6M+1.9% | |
| Other revenue | $1.15M-72.1% | $4.13M-0.8% | $4.16M-7.1% | $4.48M+6.6% | $4.2M+215% | |
| Sancuso | $12.58M+5.6% | $11.91M+8.3% | $11M+6.1% | $10.36M+9.9% | $9.43M+4.8% | |
| Vibativ | $10.23M-7.9% | $11.11M+7.1% | $10.37M+17.8% | $8.8M+2.9% | $8.55M+19.5% | |
| Non-current inventories by Product | ||||||
| Acetadote | $116.91K-3.3% | $120.88K+0.2% | $120.64K+46.2% | $82.54K-25.8% | $111.19K+1.9% | |
| Caldolor | $489.01K-14.5% | $572K+6.6% | $536.62K+13.5% | $472.71K+15.8% | $408.1K+44.1% | |
| Ifetroban | $212.3K-34.0% | $321.82K-28.1% | $447.87K-23.6% | $585.98K-19.1% | $724.09K— | |
| Kristalose | $9.46M-1.6% | $9.62M-4.1% | $10.03M-4.6% | $10.52M-2.4% | $10.79M-6.8% | |
| Sancuso | $1.88M+14.0% | $1.65M+13.6% | $1.45M-19.0% | $1.8M-10.5% | $2.01M-8.8% | |
| Vaprisol | $4.69M0.0% | $4.69M0.0% | $4.69M0.0% | $4.69M0.0% | $4.69M— | |
| Vibativ | $20.14M+1.0% | $19.94M-6.1% | $21.23M-6.7% | $22.75M-7.3% | $24.55M-4.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Cumberland Pharmaceuticals break its business down?
- Cumberland Pharmaceuticals (CPIX) reports revenue by product across 7 parts — Acetadote, Caldolor, Kristalose, Other revenue and Sancuso. Each is extracted from the segment footnotes and tracked over time.
- Where does Cumberland Pharmaceuticals's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Cumberland Pharmaceuticals's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
